Company news

ImmuneOnco appointed Mr. Huang Cheng as the vice general manager in charge of clinical medicine department

Date:2020-05-26 Views:181

 ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. announced the appointment of Mr. Huang Cheng as the vice general manager in charge of clinical medicine department.


      Mr. Huang Cheng has more than 20 years' experience in clinical drug development. He has successively engaged in clinical trial research in multinational pharmaceutical enterprises such as AstraZeneca, Boehringer Ingelheim, Abbott, Hutchison Medipharma, and Generon, involving in the treatment fields of anti-tumor, respiratory, digestive, cardiovascular, rheumatic and immune diseases, among which, he has participated in and led several domestic and international pharmaceutical enterprises Clinical trials registered or carried out in foreign countries include: Nexium, Himura, sufentinib, furquitinib, voritinib, etc., long-acting G-CSF fusion protein, IL-22 fusion protein, CD3 × EpCAM and CD3 × CD19 bispecific antibodies. Before joining ImmuneOnco, Mr. Huang Cheng was the head of Medical Department of Li's pharmaceutical group. Mr. Huang Cheng graduated from Shanghai Second Medical University (now medical school of Shanghai Jiaotong University) with a medical degree, and then obtained a master's degree in public health from Fudan University. He has successively engaged in clinical medical work in medical institutions and clinical trial research in pharmaceutical enterprises.

      "I am very honored to join the team of ImmuneOnco, which focuses on original drug research, especially in the innovative drug research with CD47 target as the core, and has its own unique advantages and characteristics. With the rapid development of ImmuneOnco, I hope I can contribute to the greater strength of ImmuneOnco. " Mr. Huang Cheng said.


      He Heming, senior clinical research director, has been engaged in clinical research for more than 20 years. In 2000, he worked as the clinical manager of Shuguang pharmaceutical research and Development Co., Ltd., engaged in clinical research; in 2004, he worked as the clinical manager and director of medical center of Huiren Group Co., Ltd.; in 2008, he worked as the clinical medicine manager of Shanghai Aishen Technology Development Co., Ltd. Since more than 20 years of clinical research on drugs, he has been responsible for more than 30 clinical studies on drugs, biological immune products and medical devices.


      Mr. Chen Wanxiang, clinical research manager, has been engaged in clinical drug research for 16 years. In 2003, he served as the director of clinical research department of biopharmaceutical in Jindalu, Anhui Province; in 2006, he served as the supervision manager of Shenzhen Tianming pharmaceutical science and technology; in 2016, he worked in zero krypton technology, successively serving as regional supervision manager and regional manager. Since he was engaged in drug clinical research, he has been in charge of five projects and participated in more than ten clinical studies of drugs and biological immune products.


      "IMM01 and IMM0306, the anti-tumor drugs independently developed by yimingengke, are currently in Phase I clinical trial research. Several other original drug projects of the company are in the pre clinical research stage, and will gradually enter the clinical trial research stage in the future," said Dr. Tian Wenzhi, the founder of ImmuneOnco, "Mr. Huang Cheng and our strong clinical trial research team are in the clinical research rich experience will play a positive and important role in promoting the company's clinical strategy. We will further strengthen the strength of the company in clinical trials and research, and maintain the leading position of our products in the clinical stage. "


About ImmuneOnco

      ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. was founded in June 2015 and registered in Zhangjiang High Tech Park, Shanghai. The company is mainly committed to the development and research of tumor immunotherapy products. The product line mainly includes bispecific antibody, new recombinant protein, and tank cell therapy. The common feature of our products is to stimulate and mobilize the immune system of patients to play an anti-tumor effect, and ultimately inhibit the continued growth of tumor cells, reverse a series of malignant symptoms caused by this, so that patients gradually return to a healthy state of the body.


Contact us

Address: Room 502, 1043 HaLei Road, Pudong New Area, Shanghai, China

Tel. + 86 21 5835 6573